Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ZSP1273 granules in children and adolescents with uncomplicated influenza A
CTR20243271Phase 2Completed
- Sponsor
- Raynovent Biotech
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlatrelvir in Influenza A infection, sponsored by Raynovent Biotech. Started Sep 2024; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on CTR20243271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243271.